文献速递急性肾损伤肾血管病与高血压

急性心衰入院时肾小管生物标志物不能预测急性肾损伤或院内不良事件

Admission kidney tubule biomarkers do not predict acute kidney injury or in-hospital adverse events in acute heart failure.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本研究为巢式病例对照研究,纳入急性心衰患者中214例发生AKI者与214例对照,评估入院时6种血和14种尿生物标志物与AKI及院内不良事件的关系。结果显示仅最高三分位的FENa和尿MCP-1与AKI风险轻度相关但判别力差,BNP可预测复合不良事件,提示心衰中肌酐变化多为功能性。

要点

  • 入院时肾小管生物标志物对急性心衰患者AKI的预测价值有限。
  • 仅FENa≥3.65%和尿MCP-1≥433 ng/g与AKI风险相关,但ROC-AUC<0.60。
  • BNP≥932 pg/ml可预测院内复合不良事件。

核心结论

  • 急性心衰入院时肾小管和心脏生物标志物与肌酐升高或院内不良事件风险无关,肌酐变化多为功能性。

研究设计与样本

  • 巢式病例对照研究,从AKI-NGAL评估症状性心衰研究中识别214例7天内发生至少1期AKI的病例和214例未发生AKI的对照。

主要发现

  • 与最低三分位相比,仅FENa最高三分位(≥3.65%)与AKI风险相关(OR 1.7,95%CI 1.0-2.9)。
  • 仅尿MCP-1最高三分位(≥433 ng/g)与AKI风险相关(OR 1.7,95%CI 1.0-2.8),但判别力差(ROC-AUC<0.60)。
  • FENa和尿MCP-1均与严重AKI无关。
  • 仅BNP升高(≥932 pg/ml)预测院内复合不良事件(OR 2.3,95%CI 1.2-4.2)。

关键数值与推荐

  • AKI定义采用2012年KDIGO标准,为入院7天内至少1期AKI。
  • AKI病例中181例(85%)为1期,16例(7%)为2期,17例(8%)为3期。

临床怎么用

  • 急性心衰患者入院时常规检测肾小管生物标志物对预测AKI和院内不良事件帮助有限。
  • BNP升高(≥932 pg/ml)可提示院内不良事件风险增加。

局限性

  • 巢式病例对照设计可能影响因果推断。
  • 生物标志物判别力低(ROC-AUC<0.60),临床实用性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Serum creatinine frequently increases during hospitalizations for acute heart failure (AHF) meeting criteria for acute kidney injury (AKI), but the significance of this increase is variable. We evaluated whether admission levels of kidney tubule and cardiac biomarkers are associated with increases in serum creatinine and adverse in-hospital events. METHODS: In a nested case-control study, we identified 214 cases with at least stage 1 AKI defined by the 2012 Kidney Disease Improving Global Outcomes criteria within 7 days of admission in the Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study and matched with 214 controls who did not experience AKI. The primary outcome was the development of AKI within the first 7 days; secondary outcomes were the development of severe AKI (stages 2 or 3) and a composite of adverse in-hospital events. Associations of 6 blood and 14 urine biomarkers were assessed with logistic regression and receiver operating characteristic area under the curve (ROC-AUC) curve analysis. RESULTS: Individuals were 71 ± 13 years; 64% were men; with median admission creatinine 1.3 (interquartile range 1.0-1.8) mg/dl. Among AKI cases, 181 (85%), 16 (7%), and 17 (8%) were stages 1, 2, and 3, respectively. Compared to the lowest tertile, only the highest tertiles of fractional excretion of sodium [FENa ≥ 3.65%; odds ratio (OR) 1.7, 95% confidence interval (CI) 1.0-2.9] and urinary monocyte chemoattractant protein-1 (≥433 ng/g; OR 1.7, 95% CI 1.0-2.8) were associated with AKI risk, though discrimination was poor (ROC-AUC < 0.60). Neither was associated with severe AKI. Only elevated B-type natriuretic peptide (≥932 pg/ml) predicted the composite adverse in-hospital event (OR 2.3, 95% CI 1.2-4.2). CONCLUSION: Kidney tubule and cardiac biomarkers at admission for AHF are not associated with risk for increases in creatinine or adverse in-hospital events reaffirming that creatinine changes in AHF are largely functional in nature.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Duff S, Wettersten N, Horiuchi Y, et al. Admission kidney tubule biomarkers do not predict acute kidney injury or in-hospital adverse events in acute heart failure. Nephrol Dial Transplant. 2026. PMID: 41990458. doi:10.1093/ndt/gfag079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。